Bernard A. Fox: Dark Matter is the biggest breakthrough in cancer immunotherapy of the last 3 years

Bernard A. Fox, Co-Founder and CEO of UbiVac shared on LinkedIn:

“Best response rate for recurrent or metastatic Head and Neck Squamous Cell Carcinomas at AACR2024 was combination immunotherapy with UbiVac’s DPV-001 Dark Matter cancer vaccine/immunotherapy. I believe that the discovery of Cancer’s Dark Matter is the biggest breakthrough in cancer immunotherapy of the last 3 years and it has the potential to change how all cancers are treated.

DPV-001 is the first Dark Matter cancer vaccine given to patients and is an off-the-shelf immunotherapy designed to be a universal therapeutic vaccine for the majority of solid cancers. While we need to treat additional patients to confirm these promising results, we consider that DPV-001 is the only treatment containing cancer’s “Dark Matter” in a form that does not require HLA-matching, can stimulate broad immune reactivity, and we are actively investigating whether immunity to Dark Matter is responsible for the increased response rates in patients with cancer.

DPV-001 also contains 300+ shared cancer antigens and may be useful to boost TIL following adoptive immunotherapy. UbiVac is seeking funding for a series B round to expand operations, manufacture vaccine, and build a team to take DPV-001 to approval.”

Further Reading.
Source: Bernard A. Fox/LinkedIn